Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Jan 30, 2025

SELL
$6.27 - $10.92 $70,224 - $122,304
-11,200 Closed
0 $0
Q2 2018

Jan 30, 2025

BUY
$8.55 - $13.76 $95,760 - $154,112
11,200 New
11,200 $127 Million

Others Institutions Holding SVRA

About Savara Inc


  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $310M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track Silphium Asset Management LTD Portfolio

Follow Silphium Asset Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Silphium Asset Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Silphium Asset Management LTD with notifications on news.